CN107951861B - 一种脂质纳米粒膜材料组合物 - Google Patents
一种脂质纳米粒膜材料组合物 Download PDFInfo
- Publication number
- CN107951861B CN107951861B CN201610902492.2A CN201610902492A CN107951861B CN 107951861 B CN107951861 B CN 107951861B CN 201610902492 A CN201610902492 A CN 201610902492A CN 107951861 B CN107951861 B CN 107951861B
- Authority
- CN
- China
- Prior art keywords
- tween
- material composition
- membrane material
- cholesterol
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 54
- 239000012528 membrane Substances 0.000 title claims abstract description 52
- 239000000463 material Substances 0.000 title claims abstract description 51
- 150000002632 lipids Chemical class 0.000 title claims abstract description 40
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 96
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 48
- 229920001223 polyethylene glycol Chemical class 0.000 claims abstract description 37
- 229920000136 polysorbate Chemical class 0.000 claims abstract description 30
- 239000002202 Polyethylene glycol Chemical class 0.000 claims abstract description 23
- -1 cationic lipid Chemical class 0.000 claims abstract description 19
- 150000002334 glycols Chemical class 0.000 claims abstract description 18
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 230000007935 neutral effect Effects 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 45
- 229920000053 polysorbate 80 Polymers 0.000 claims description 45
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 41
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 36
- 239000011259 mixed solution Substances 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 12
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 238000007865 diluting Methods 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 239000012266 salt solution Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 6
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 5
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 4
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 claims description 3
- HYXWVUFYXOOASK-UHFFFAOYSA-N CCCCCCCCCCCCCC(=O)OCC(COCCOC)OC(=O)CCCCCCCCCCCCC Chemical compound CCCCCCCCCCCCCC(=O)OCC(COCCOC)OC(=O)CCCCCCCCCCCCC HYXWVUFYXOOASK-UHFFFAOYSA-N 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 1
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000002245 particle Substances 0.000 description 29
- 238000005538 encapsulation Methods 0.000 description 17
- 238000013112 stability test Methods 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 150000003841 chloride salts Chemical class 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- HKJAWHYHRVVDHK-UHFFFAOYSA-N 15,16,17-trihydroxyhentriacontane-14,18-dione Chemical compound CCCCCCCCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCCCCCCCC HKJAWHYHRVVDHK-UHFFFAOYSA-N 0.000 description 1
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 1
- 102100021391 Cationic amino acid transporter 3 Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 description 1
- 108091006230 SLC7A3 Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- XRWMGCFJVKDVMD-UHFFFAOYSA-M didodecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCC XRWMGCFJVKDVMD-UHFFFAOYSA-M 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 123.4 | 7.45 | 89.2% |
2 | 132.5 | 7.96 | 83.8% |
3 | 128.1 | 8.55 | 84.9% |
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 120.4 | 7.78 | 80.4% |
2 | 123.4 | 7.45 | 89.2% |
3 | 143.4 | 7.03 | 86.2% |
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 135.4 | 9.23 | 78.4% |
2 | 128.0 | 8.53 | 84.7% |
3 | 123.4 | 7.45 | 89.2% |
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 129.2 | 8.53 | 82.6% |
2 | 124.6 | 7.91 | 79.3% |
3 | 123.4 | 7.45 | 89.2% |
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 131.4 | 5.76 | 88.4% |
2 | 127.2 | 6.66 | 91.9% |
3 | 126.4 | 6.75 | 84.6% |
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 124.4 | 7.12 | 82.8% |
2 | 126.0 | 8.04 | 87.1% |
3 | 131.8 | 7.71 | 89.9% |
制剂 | 粒径(nm) | 电位(mV) | 包封率(%) |
1 | 142.6 | 7.68 | 85.2% |
2 | 134.5 | 6.63 | 87.3% |
3 | 135.8 | 7.90 | 91.4% |
Claims (14)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610902492.2A CN107951861B (zh) | 2016-10-17 | 2016-10-17 | 一种脂质纳米粒膜材料组合物 |
PCT/CN2017/106032 WO2018072644A1 (zh) | 2016-10-17 | 2017-10-13 | 一种脂质纳米粒膜材料组合物 |
JP2019541840A JP6893245B2 (ja) | 2016-10-17 | 2017-10-13 | 脂質ナノ粒子用膜材料組成物 |
EP17863062.0A EP3527201B1 (en) | 2016-10-17 | 2017-10-13 | Lipid nanoparticle film material composition |
US16/342,804 US20200237678A1 (en) | 2016-10-17 | 2017-10-13 | Lipid nanoparticle membrane composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610902492.2A CN107951861B (zh) | 2016-10-17 | 2016-10-17 | 一种脂质纳米粒膜材料组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107951861A CN107951861A (zh) | 2018-04-24 |
CN107951861B true CN107951861B (zh) | 2020-12-01 |
Family
ID=61953463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610902492.2A Active CN107951861B (zh) | 2016-10-17 | 2016-10-17 | 一种脂质纳米粒膜材料组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200237678A1 (zh) |
EP (1) | EP3527201B1 (zh) |
JP (1) | JP6893245B2 (zh) |
CN (1) | CN107951861B (zh) |
WO (1) | WO2018072644A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111544317B (zh) * | 2020-04-29 | 2022-01-14 | 珀莱雅化妆品股份有限公司 | 一种抗衰老组合物阳离子纳米脂质体及其制备方法与应用 |
CN112336853A (zh) * | 2020-10-21 | 2021-02-09 | 中南大学湘雅三医院 | 一种脂质体纳米疫苗、制备方法及应用 |
CN117491546A (zh) * | 2023-06-30 | 2024-02-02 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质含量的检测方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101538303A (zh) * | 2007-12-25 | 2009-09-23 | 沈阳药科大学 | 一种葫芦素族单体天然脂肪酸单酯的衍生物 |
CN102215820A (zh) * | 2008-11-17 | 2011-10-12 | 安龙制药公司 | 用于核酸输送系统的可释放融合脂质 |
CN102670510A (zh) * | 2012-05-02 | 2012-09-19 | 江苏省中医药研究院 | 穿膜肽修饰的雷公藤红素纳米结构脂质载体及在制备治疗前列腺癌、肺癌、乳腺癌药的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009120247A2 (en) * | 2007-12-27 | 2009-10-01 | The Ohio State University Research Foundation | Lipid nanoparticle compositions and methods of making and using the same |
CN101732349B (zh) * | 2008-11-14 | 2012-05-23 | 上海医药工业研究院 | 一种蟾酥纳米长循环脂质体及其制备方法 |
US9610367B2 (en) * | 2010-08-24 | 2017-04-04 | Canon Kabushiki Kaisha | Particle and contrast agent having the particle |
JP6294456B2 (ja) * | 2013-03-13 | 2018-03-14 | マリンクロッド エルエルシー | 修飾されたドセタキセルリポソーム製剤 |
US10111871B2 (en) * | 2013-08-27 | 2018-10-30 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
JP2017501172A (ja) * | 2013-12-16 | 2017-01-12 | メルク パテント ゲーエムベーハー | サバイビン指向性癌ワクチン治療 |
-
2016
- 2016-10-17 CN CN201610902492.2A patent/CN107951861B/zh active Active
-
2017
- 2017-10-13 JP JP2019541840A patent/JP6893245B2/ja active Active
- 2017-10-13 WO PCT/CN2017/106032 patent/WO2018072644A1/zh active Application Filing
- 2017-10-13 EP EP17863062.0A patent/EP3527201B1/en active Active
- 2017-10-13 US US16/342,804 patent/US20200237678A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101538303A (zh) * | 2007-12-25 | 2009-09-23 | 沈阳药科大学 | 一种葫芦素族单体天然脂肪酸单酯的衍生物 |
CN102215820A (zh) * | 2008-11-17 | 2011-10-12 | 安龙制药公司 | 用于核酸输送系统的可释放融合脂质 |
CN102670510A (zh) * | 2012-05-02 | 2012-09-19 | 江苏省中医药研究院 | 穿膜肽修饰的雷公藤红素纳米结构脂质载体及在制备治疗前列腺癌、肺癌、乳腺癌药的应用 |
Non-Patent Citations (1)
Title |
---|
The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery;Xinwei Cheng等;《Advanced Drug Delivery Reviews》;20160218;第99卷;全文,特别是摘要,第133页 * |
Also Published As
Publication number | Publication date |
---|---|
US20200237678A1 (en) | 2020-07-30 |
JP2019534899A (ja) | 2019-12-05 |
JP6893245B2 (ja) | 2021-06-23 |
EP3527201B1 (en) | 2021-08-18 |
EP3527201A4 (en) | 2020-05-27 |
EP3527201A1 (en) | 2019-08-21 |
WO2018072644A1 (zh) | 2018-04-26 |
CN107951861A (zh) | 2018-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lujan et al. | Synthesis and characterization of nanometer-sized liposomes for encapsulation and microRNA transfer to breast cancer cells | |
Grijalvo et al. | Cationic niosomes as non-viral vehicles for nucleic acids: Challenges and opportunities in gene delivery | |
Douliez et al. | Catanionic coacervate droplets as a surfactant‐based membrane‐free protocell model | |
CN107951861B (zh) | 一种脂质纳米粒膜材料组合物 | |
CN101239041B (zh) | 一种高分子脂质体及其应用 | |
EP3391875B1 (en) | Method for preparing polymeric micelle containing anionic drug | |
Haghiralsadat et al. | Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy | |
EP2502617B1 (en) | Process for production of w/o/w emulsion, process for production of liposome employing the process, and porous membrane for use in the methods | |
CN101903018A (zh) | 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法 | |
JP6986563B2 (ja) | bcl−2を抑制するアンチセンスオリゴヌクレオチドの脂質ナノ粒子及びその調製方法 | |
Rahman et al. | Nucleic acid-loaded lipid-polymer nanohybrids as novel nanotherapeutics in anticancer therapy | |
CN105287382A (zh) | 叶酸-壳聚糖修饰姜黄素纳米脂质体的制备方法 | |
JP5494054B2 (ja) | 二段階乳化によるリポソーム製造方法 | |
US20120232260A1 (en) | Amphiphilic nucleotide cochleate compositions and methods of using the same | |
Lebrón et al. | Metallo-liposomes of ruthenium used as promising vectors of genetic material | |
CN105434437A (zh) | 一种奥沙利铂和伊立替康类药物共载脂质体及其制备方法 | |
CN103565744A (zh) | 大分子磷脂酰甘油纳米脂质体、制备方法及应用 | |
US8227248B2 (en) | Composition for nucleic-acid transfection | |
CN102485213A (zh) | 伊立替康脂质体及其制备方法 | |
JP2012102043A (ja) | 単胞リポソームの製造方法、単胞リポソームの分散液とその乾燥粉末及びそれらの製造方法 | |
Yau et al. | In-Space Fabrication of Janus Base Nano-Matrix for Improved Assembly and Bioactivities | |
KR20230130538A (ko) | mRNA 전달 효율 증대를 위한 mRNA 전달체용 지질 나노입자의 제조방법 | |
CN117982460A (zh) | 一种球棍状脂质纳米颗粒的制备及应用 | |
CN102525931A (zh) | 一种戊铂脂质体制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240620 Address after: No. 28, Gaoxin Road, Jiangbei new district, Nanjing, Jiangsu 210061 Patentee after: NANJING LUYE PHARMACEUTICAL Co.,Ltd. Country or region after: China Patentee after: Nanjing Jimai Biotechnology Co.,Ltd. Address before: No. 28, Gaoxin Road, high tech Development Zone, Nanjing, Jiangsu 210061 Patentee before: NANJING LUYE PHARMACEUTICAL Co.,Ltd. Country or region before: China Patentee before: NANJING ASEC NANO BIOMEDICINE Co.,Ltd. |